Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20721195 | 0.95 | SLC7A5 (0.30) | SLC7A5 | |
| SCHEMBL11386619 | 0.79 | — | — | |
| SCHEMBL11180390 | 0.79 | — | — | |
| SCHEMBL18306044 | 0.76 | — | — | |
| SCHEMBL1153835 | 0.76 | — | — | |
| SCHEMBL23542640 | 0.76 | — | — | |
| SCHEMBL13007450 | 0.76 | — | — | |
| SCHEMBL18305963 | 0.76 | — | — | |
| SCHEMBL1153840 | 0.76 | — | — | |
| SCHEMBL12364122 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680211-B2 | Hybrid polyester-polyether polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-03-25 | — | — | US | claimed |
| EP-2563834-A1 | HYBRID POLYESTER-POLYETHER POLYOLS | Dow Global Technologies LLC (US) | 2013-03-06 | — | — | EP | claimed |
| US-20130035467-A1 | HYBRID POLYESTER-POLYETHER POLYOLS | DOW EUROPE GMBH (CH) | 2013-02-07 | — | — | US | claimed |
| WO-2011137011-A1 | HYBRID POLYESTER-POLYETHER POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-11-03 | — | — | WO | claimed |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-4517379-A | ARTIFICIAL SWEETENER | PFIZER INC. (US) | 1985-05-14 | — | — | US | disclosed |
| EP-0069811-B1 | BRANCHED AMIDES OF L-ASPARTYL-D-AMINO ACID DIPEPTIDES AND COMPOSITIONS THEREOF | PFIZER INC. (US) | 1984-10-24 | — | — | EP | disclosed |
| EP-0034876-B1 | BRANCHED AMIDES OF L-ASPARTYL-D-AMINO ACID DIPEPTIDES AND COMPOSITIONS THEREOF | PFIZER INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| US-4454328-A | SWEETENERS | PFIZER INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4411925-A | STABLE SWEETENERS | PFIZER INC. (US) | 1983-10-25 | — | — | US | disclosed |
| US-4399163-A | ARTIFICIAL SWEETENERS | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| EP-0069811-A1 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0034876-A2 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1981-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271977-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | SLC7A5 784/4885LAP3 759/4885 |
| US-11814394-B2 | Exatecan derivatives, linker-payloads, and conjugates and thereof | XPOT, ENGASE, ENTPD8 | SLC7A5 784/4885LAP3 759/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SLC7A5 2258/4885LAP3 1382/4885 |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | SLC7A5 1253/4885LAP3 199/4885 |
| US-20240018159-A1 | EXATECAN DERIVATIVES, LINKER-PAYLOADS, AND CONJUGATES AND THEREOF | XPOT, ENGASE, ENTPD8 | SLC7A5 784/4885LAP3 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.